- Home
- XBIO vs SCNI Comparison
XBIO vs SCNI Comparison
Compare XBIO & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- SCNI
- Stock Information
- Founded
- XBIO N/A
- SCNI 2003
- Country
- XBIO United States
- SCNI Israel
- Employees
- XBIO N/A
- SCNI N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XBIO Health Care
- SCNI Health Care
- Exchange
- XBIO Nasdaq
- SCNI Nasdaq
- Market Cap
- XBIO 4.4M
- SCNI 4.6M
- IPO Year
- XBIO N/A
- SCNI N/A
- Fundamental
- Price
- XBIO $3.48
- SCNI $1.46
- Analyst Decision
- XBIO Hold
- SCNI
- Analyst Count
- XBIO 1
- SCNI 0
- Target Price
- XBIO N/A
- SCNI N/A
- AVG Volume (30 Days)
- XBIO 2.6M
- SCNI 102.0K
- Earning Date
- XBIO 11-10-2025
- SCNI 11-21-2025
- Dividend Yield
- XBIO N/A
- SCNI N/A
- EPS Growth
- XBIO N/A
- SCNI N/A
- EPS
- XBIO N/A
- SCNI 0.26
- Revenue
- XBIO $2,446,221.00
- SCNI $1,147,000.00
- Revenue This Year
- XBIO $1.99
- SCNI N/A
- Revenue Next Year
- XBIO $20.00
- SCNI N/A
- P/E Ratio
- XBIO N/A
- SCNI $5.54
- Revenue Growth
- XBIO N/A
- SCNI 303.87
- 52 Week Low
- XBIO $2.20
- SCNI $1.20
- 52 Week High
- XBIO $13.93
- SCNI $6.18
- Technical
- Relative Strength Index (RSI)
- XBIO 44.23
- SCNI 50.68
- Support Level
- XBIO $3.56
- SCNI $1.43
- Resistance Level
- XBIO $4.15
- SCNI $1.52
- Average True Range (ATR)
- XBIO 0.67
- SCNI 0.09
- MACD
- XBIO -0.24
- SCNI 0.01
- Stochastic Oscillator
- XBIO 1.28
- SCNI 57.14
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.